论文部分内容阅读
目的:研究早期糖尿病大鼠视网膜和脉络膜血管中VEGFR-2的表达。方法:24只雄性Wistar大鼠,随机分为两组:正常对照组和糖尿病组。实验组给予一次性静脉注射60 mg/kg STZ建立糖尿病模型。STZ注射后24 h,血糖水平超过250 mg/dL被认为是糖尿病模型。WB技术检测VEGFR-2在视网膜和脉络膜的表达水平,免疫组化法用来定位VEGFR-2。结果:STZ注射14天后,糖尿病组的平均体重较对照组显著降低(糖尿病组:177±10 g,对照组:243±19 g,P<0.05),糖尿病组的平均血糖水平较对照组显著增高(糖尿病组的血糖为498±36 mg/m L,对照组的血糖为90±10 mg/m L,P<0.05)。VEGFR-2在糖尿病鼠的视网膜和脉络膜中表达较对照组增加,其差异有统计学意义(P<0.05)。免疫组化分析显示:VEGFR-2在糖尿病组的视网膜和脉络膜血管中表达显著增加,而在正常对照组中少量表达(P<0.05)。结论:VEGFR-2在试验诱导的糖尿病模型的视网膜和脉络膜血管中的表达增加,VEGFR-2可能成为糖尿病视网膜病变新的诊断靶点。
Objective: To investigate the expression of VEGFR-2 in retina and choroidal blood vessels of early diabetic rats. Methods: Twenty-four male Wistar rats were randomly divided into two groups: normal control group and diabetic group. The experimental group was given a single intravenous injection of 60 mg / kg STZ to establish a diabetic model. 24 h after STZ injection, blood glucose levels exceeding 250 mg / dL are considered as diabetic models. WB was used to detect the expression of VEGFR-2 in the retina and choroid, and immunohistochemistry was used to locate VEGFR-2. Results: After 14 days of STZ injection, the mean body weight of the diabetic group was significantly lower than that of the control group (177 ± 10 g in the diabetic group and 243 ± 19 g in the control group, P <0.05). The average blood glucose level in the diabetic group was significantly higher than that in the control group (Blood glucose was 498 ± 36 mg / m L in diabetic group and 90 ± 10 mg / m L in control group, P <0.05). The expression of VEGFR-2 in the retina and choroid of diabetic mice increased compared with the control group, the difference was statistically significant (P <0.05). Immunohistochemical analysis showed that the expression of VEGFR-2 was significantly increased in the retina and choroidal vessels of diabetic group, while it was slightly expressed in the normal control group (P <0.05). CONCLUSIONS: VEGFR-2 is up-regulated in the retinas and choroidal vessels of experimental diabetic models, and VEGFR-2 may be a novel diagnostic target for diabetic retinopathy.